Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 20, 2007

Cannasat Taps IntelGenx to Facilitate Development of Cannabinoid-Based Products for Mood Disorders

  • Cannasat Therapeutics and IntelGenx will together develop a cannabinoid-based product through a combination of Cannasat's and IntelGenx's drug delivery technologies. CAT 320 targets the endocannabinoid system to treat mood disorders, such as anxiety and depression.

    Cannasat will leverage IntelGenx' experience in developing oral, sublingual, and transdermal formulations. IntelGenx' will help address the challenges of achieving rapid onset, improving therapeutic efficacy, and minimizing the total dose required to treat disease conditions.

  • You’re all set! Thank you for subscribing to GEN Highlights.